The Neurohospitalist · 2011 · 223 citations · 41 references
MedicinePharmacologyPharmacotherapyNeurocritical CareNeuropharmacologyPsychopharmacologyAntipsychotic PharmacologyAntipsychotic PharmacotherapyAntipsychotic TherapyAntipsychotic Medication ManagementAntipsychotic Medication UseDifferential Diagnosis CriteriaIdiosyncratic ToxicityMental Status ChangesPsychotropic Medication ToxicitySupportive Management
Neuroleptic malignant syndrome (NMS) is a life-threatening idiosyncratic reaction to antipsychotic drugs characterized by fever, altered mental status, muscle rigidity, and autonomic dysfunction. It has been associated with virtually all neuroleptics, including newer atypical antipsychotics, as well as a variety of other medications that affect central dopaminergic neurotransmission. Although uncommon, NMS remains a critical consideration in the differential diagnosis of patients presenting with fever and mental status changes because it requires prompt recognition to prevent significant morbidity and death. Treatment includes immediately stopping the offending agent and implementing supportive measures, as well as pharmacological interventions in more severe cases. Maintaining vigilant awareness of the clinical features of NMS to diagnose and treat the disorder early, however, remains the most important strategy by which physicians can keep mortality rates low and improve patient outcomes.
41
Neuroleptic malignant syndrome
Victor W. Henderson, G. Frederick Wooten · Neurology · 1981 · 343 citations
Medicine, Neurology, Pharmacology +16
Mortality from neuroleptic malignant syndrome.
Arieh Y. Shalev, Haggai Hermesh, Hanan Munitz · PubMed · 1989 · 287 citations
Medicine, Neurology, Pharmacology +11
Risk Factors for Neuroleptic Malignant Syndrome
Paul E. Keck · Archives of General Psychiatry · 1989 · 268 citations
Medicine, Neurology, Psychiatry +7